TG Therapeutics (TGTX)
NASDAQ:TGTX
Want to see TGTX full AI Analyst Report?
TGTX Stock Chart & Stats
$35.33
$0.31(1.11%)
At close: 4:00 PM EST
$35.33
$0.31(1.11%)
Day’s Range― - ―
52-Week Range$25.28 - $44.65
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.10M
Market Cap
$5.95B
Enterprise Value$6.26B
Total Cash (Recent Filing)$514.43M
Total Debt (Recent Filing)$753.56M
Price to Earnings (P/E)60.7
Beta0.71
Next Earnings
Aug 10, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.18
Shares Outstanding153,083,570
10 Day Avg. Volume1,711,241
30 Day Avg. Volume2,101,420
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)6.64
Price to Sales (P/S)6.98
P/FCF Ratio-172.18
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue8.94
Enterprise Value/Gross Profit10.77
Enterprise Value/Ebitda39.92
Forecast
1Y Price Target
$44.25Price Target Upside25.25% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)1.3
Revenue Forecast (FY)$935.26M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And Awareness ProgramsAnalyst points to broad regulatory approvals across multiple countries and a direct-to-patient awareness program featuring a well-known advocate as catalysts to increase prescribing uptake and US growth for Briumvi.
Competitor Safety ConcernsAnalyst highlights safety concerns around fenebrutinib, including liver monitoring signals and an imbalance in fatalities, that could limit adoption of oral BTK therapies and favor continued uptake of Briumvi.
Real-world Evidence And Prescriber AdoptionAnalyst cites real-world data showing Briumvi clinical outcomes consistent with pivotal trials and reports of rising new patient starts and durable treatment persistence, supporting further market share gains among high-prescribing clinicians.
Bears Say
Direct Efficacy Competition From Oral BTKAnalyst notes fenebrutinib demonstrated relapse-rate reductions and imaging improvements similar to Briumvi in pivotal trials, creating a direct efficacy-based threat to Briumvi's market position.
Patient Switching Risk To Oral PillsAnalyst emphasizes strong patient demand for convenient alternatives to infusions, meaning an effective and safe oral BTK pill could drive substantial switching away from injectable CD20 therapies like Briumvi.
Rival Product Expansion PressureAnalyst highlights Roche's expansion of subcutaneous and oral treatment options as an additional competitive pressure that could erode Briumvi's addressable market.
TG Therapeutics News
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $25.28 and its highest was $44.65 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $5.95B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is Aug 10, 2026 which is in 77 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on May 06, 2026. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.275 by -$0.155.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.33.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 153,083,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.12 in its last earnings report, missing expectations of $0.275. Following the earnings report the stock price went up 16.26%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$44.25 (25.25% Upside)
$44.25 (25.25% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 536.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.52%
12-Months-Change
Fundamentals
Return on Equity
87.36%
Trailing 12-Months
Asset Growth
132.81%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TGTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.View all TGTX earnings summariesTGTX Stock 12 Month Forecast
Average Price Target
$44.25
▲(25.25% Upside)
Technical Analysis
Ionis Pharmaceuticals
―
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Nuvalent
―
Ownership Overview
7.54% Insiders
18.38% Mutual Funds
12.55% Other Institutional Investors
36.96% Public Companies and
Individual Investors